Baotou Dongbao Bio-TechLtd Management
Management criteria checks 4/4
Baotou Dongbao Bio-TechLtd's CEO is Fang Liu, appointed in Sep 2021, has a tenure of 4.33 years. directly owns 0.71% of the company’s shares, worth CN¥25.80M. The average tenure of the management team and the board of directors is 4.3 years and 4.3 years respectively.
Key information
Fang Liu
Chief executive officer
CN¥745.1k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.7% |
| Management average tenure | 4.3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price Boost
Oct 08
We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)
Oct 01Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022
May 27Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)
Feb 28CEO
Fang Liu (61 yo)
Mr. Fang Liu serves as General Manager of Baotou Dongbao Bio-Tech Co.,Ltd since September 10, 2021 and serves as its Director since August 28, 2000. He served as Secretary of the Board at Baotou Dongbao Bi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 4.3yrs | CN¥745.10k | 0.71% CN¥ 25.8m | |
| Financial Director | 6.8yrs | CN¥529.70k | no data | |
| Deputy GM & Director | 9.3yrs | CN¥509.90k | no data | |
| Deputy GM & Director | 4.3yrs | CN¥654.90k | no data | |
| Deputy GM & Board Secretary | 4.3yrs | CN¥487.30k | no data | |
| Deputy General Manager | 9.3yrs | CN¥554.40k | no data | |
| Deputy General Manager | 1.7yrs | CN¥260.90k | no data | |
| Accounting Supervisor | no data | no data | no data |
Experienced Management: 300239's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 25.4yrs | CN¥745.10k | 0.71% CN¥ 25.8m | |
| Deputy GM & Director | 11.8yrs | CN¥509.90k | no data | |
| Deputy GM & Director | 4.3yrs | CN¥654.90k | no data | |
| Independent Director | 5.7yrs | CN¥100.00k | no data | |
| Chairman of the supervisory board | 1.7yrs | no data | no data | |
| Chairman | 4.3yrs | CN¥9.60k | no data | |
| Independent Director | 4.3yrs | CN¥100.00k | no data | |
| Supervisor | 4.3yrs | no data | no data | |
| Independent Director | 1.7yrs | CN¥58.30k | no data | |
| Supervisor | 1.7yrs | no data | no data |
Experienced Board: 300239's board of directors are considered experienced (4.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/18 07:56 |
| End of Day Share Price | 2026/01/16 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Baotou Dongbao Bio-Tech Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Yao | Everbright Securities Co. Ltd. |